Amneal (AMRX) news

Amneal Pharma: JPMorgan resumes coverage with overweight rating; target price $22

JPMorgan has upgraded Amneal Pharmaceuticals (NASDAQ:AMRX) to "Overweight" from "Neutral," citing strong execution across the company's portfolio and a successful launch of its product, Crexont. The firm also raised its price target for Amneal shares to $12 from $9. The upgrade reflects confidence…

Shilpa Medicare - recall does not affect other products or supply

Shilpa Medicare Limited has initiated a voluntary recall of over 27,000 vials of its chemotherapy drug “Pemetri RTU” in the United States due to green to dark-green discoloration in certain vials. The affected batches, manufactured by Zydus Lifesciences and distributed by Amneal Pharmaceuticals,…

Shilpa Medicare - initiates voluntary recall of 27,923 pemetrexed injection vials in US on July 29, 2026

Shilpa Medicare has initiated a voluntary recall of 27,923 vials of its chemotherapy drug Pemetri RTU in the United States on July 29, 2026 . The affected vials include 18,434 units of the 10 mg strength and 9,489 units of the 50 mg strength. The recall follows reports of "green to dark-green…

Gland Pharma names Spara CEO, effective Nov 16

Gland Pharma has announced the appointment of Shyamakant Giri as its new Chief Executive Officer (CEO), effective January 15, 2025 . This decision was approved by the company’s Board of Directors based on the Nomination and Remuneration Committee . Giri brings over 25 years of experience in the…

Amneal Pharmaceuticals - converts term loans to $2.04 bln; incurs new $45.20 mln term loan - SEC filing